The Clinical Evidence Behind Every Score
GLP1Score's eligibility scoring engine is built on 20 peer-reviewed clinical studies. Every recommendation we make is traceable to published research. Browse the evidence library below.
Key Studies
- STEP 1 (NEJM 2021): 14.9% mean weight loss at 68 weeks with semaglutide 2.4mg
- SELECT (NEJM 2023): 20% reduction in major cardiovascular events in 17,604 patients
- STEP 2 (Lancet 2021): 9.6% weight loss in patients with Type 2 diabetes
- ICMR-INDIAB-17 (Lancet D&E 2023): 101.3 million Indians with diabetes, 254 million with obesity
- ICMR-INDIAB-23 (2024): 43.3% of normal-weight Indians are metabolically obese
- STEP 10 (JAMA 2024): 71% of prediabetics returned to normal glucose
- SUSTAIN-6 (NEJM 2016): 26% MACE reduction in diabetes patients
- Weight Regain (BMJ 2026): 67% of lost weight regained within 1 year of stopping
Transparency
Each study is tagged with its funding source (independent or industry-funded). Most large clinical trials are pharmaceutical-funded due to cost, but are published in top peer-reviewed journals with rigorous oversight. We label everything transparently.
Take the Free Assessment | Read Our Guides